EMEA-003568-PIP01-23
Submitted by Anonymous (not verified) on 13 May 2025 - 16:37
EMEA-003568-PIP01-23
EMEA-003603-PIP01-24
Submitted by Anonymous (not verified) on 13 May 2025 - 16:23
EMEA-003603-PIP01-24
PSUSA/00001606/202409
Submitted by Anonymous (not verified) on 13 May 2025 - 16:15
PSUSA/00001606/202409
PSUSA/00010929/202410
Submitted by Anonymous (not verified) on 13 May 2025 - 16:12
PSUSA/00010929/202410
PSUSA/00010348/202409
Submitted by Anonymous (not verified) on 13 May 2025 - 16:12
PSUSA/00010348/202409
Human medicines European public assessment report (EPAR): Clopidogrel Krka d.d. (previously Zopya), clopidogrel, Date of authorisation: 20/09/2009, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 13 May 2025 - 16:10
Human medicines European public assessment report (EPAR): Clopidogrel Krka d.d. (previously Zopya), clopidogrel, Date of authorisation: 20/09/2009, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Clopidogrel TAD, clopidogrel, Date of authorisation: 23/09/2009, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 13 May 2025 - 16:05
Human medicines European public assessment report (EPAR): Clopidogrel TAD, clopidogrel, Date of authorisation: 23/09/2009, Revision: 17, Status: Authorised
EMEA-002876-PIP02-23
Submitted by Anonymous (not verified) on 13 May 2025 - 15:48
EMEA-002876-PIP02-23
Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 13 May 2025 - 15:45
Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 11, Status: Authorised
EMEA-002689-PIP02-23
Submitted by Anonymous (not verified) on 13 May 2025 - 15:06
EMEA-002689-PIP02-23